Poniard Pharmaceuticals, Inc.
PARDOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$150
P/E Ratio—
52W High$0.0001
52W Low$0.00001
Poniard Pharmaceuticals, Inc. (PARD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PARD · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2011Report Date: Mar 30, 2011EPS Actual
-$4.40
Est. -$5.00 · +12.0%
Revenue
—
Fiscal Period
Q1 FY2011
FY ends December
Report Date
Mar 30, 2011
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
PARD reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q1 FY2011 | Mar 30, 2011 | -$5.00 | -$4.40 | +12.0% | — | — | — |
| ▲ Q4 FY2010 | Nov 9, 2010 | -$6.59 | -$5.20 | +21.1% | — | — | — |
| ▲ Q3 FY2010 | Aug 9, 2010 | -$7.86 | -$5.60 | +28.8% | — | — | — |
| ▼ Q2 FY2010 | May 10, 2010 | -$9.16 | -$11.60 | -26.6% | — | — | — |
| ▲ Q4 FY2009 | Nov 3, 2009 | -$11.73 | -$11.60 | +1.1% | — | — | — |
| ▲ Q3 FY2009 | Aug 4, 2009 | -$13.72 | -$11.20 | +18.4% | — | — | — |
| — Q2 FY2009 | May 5, 2009 | -$15.13 | -$15.20 | -0.5% | — | — | — |
| ▲ Q4 FY2008 | Oct 30, 2008 | -$14.80 | -$14.40 | +2.7% | — | — | — |
Q1 FY2011
Mar 30, 2011Beat
EPS Actual
-$4.40
EPS Est.
-$5.00
EPS Surpr.
+12.0%
Revenue
—
Q4 FY2010
Nov 9, 2010Beat
EPS Actual
-$5.20
EPS Est.
-$6.59
EPS Surpr.
+21.1%
Revenue
—
Q3 FY2010
Aug 9, 2010Beat
EPS Actual
-$5.60
EPS Est.
-$7.86
EPS Surpr.
+28.8%
Revenue
—
Q2 FY2010
May 10, 2010Miss
EPS Actual
-$11.60
EPS Est.
-$9.16
EPS Surpr.
-26.6%
Revenue
—
Q4 FY2009
Nov 3, 2009Beat
EPS Actual
-$11.60
EPS Est.
-$11.73
EPS Surpr.
+1.1%
Revenue
—
Q3 FY2009
Aug 4, 2009Beat
EPS Actual
-$11.20
EPS Est.
-$13.72
EPS Surpr.
+18.4%
Revenue
—
Q2 FY2009
May 5, 2009
EPS Actual
-$15.20
EPS Est.
-$15.13
EPS Surpr.
-0.5%
Revenue
—
Q4 FY2008
Oct 30, 2008Beat
EPS Actual
-$14.40
EPS Est.
-$14.80
EPS Surpr.
+2.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2011 | Mar 30, 2011 | +12.0% | $16.12 | $17.16 | +6.45% |
| ▲ Q4 FY2010 | Nov 9, 2010 | +21.1% | $20.00 | $19.60 | -2.00% |
| ▲ Q3 FY2010 | Aug 9, 2010 | +28.8% | $24.24 | $23.20 | -4.29% |
| ▼ Q2 FY2010 | May 10, 2010 | -26.6% | $41.60 | $50.80 | +22.12% |
| ▲ Q4 FY2009 | Nov 3, 2009 | +1.1% | $66.80 | $70.70 | +5.84% |
| ▲ Q3 FY2009 | Aug 4, 2009 | +18.4% | $71.60 | $73.00 | +1.96% |
| ▲ Q2 FY2009 | May 5, 2009 | -0.5% | $32.60 | $31.50 | -3.37% |
| ▲ Q4 FY2008 | Oct 30, 2008 | +2.7% | $31.50 | $29.90 | -5.08% |
Q1 FY2011+6.45%
Report Date
Mar 30, 2011
EPS Beat/Miss
+12.0%
Price Before
$16.12
Price After
$17.16
Q4 FY2010-2.00%
Report Date
Nov 9, 2010
EPS Beat/Miss
+21.1%
Price Before
$20.00
Price After
$19.60
Q3 FY2010-4.29%
Report Date
Aug 9, 2010
EPS Beat/Miss
+28.8%
Price Before
$24.24
Price After
$23.20
Q2 FY2010+22.12%
Report Date
May 10, 2010
EPS Beat/Miss
-26.6%
Price Before
$41.60
Price After
$50.80
Q4 FY2009+5.84%
Report Date
Nov 3, 2009
EPS Beat/Miss
+1.1%
Price Before
$66.80
Price After
$70.70
Q3 FY2009+1.96%
Report Date
Aug 4, 2009
EPS Beat/Miss
+18.4%
Price Before
$71.60
Price After
$73.00
Q2 FY2009-3.37%
Report Date
May 5, 2009
EPS Beat/Miss
-0.5%
Price Before
$32.60
Price After
$31.50
Q4 FY2008-5.08%
Report Date
Oct 30, 2008
EPS Beat/Miss
+2.7%
Price Before
$31.50
Price After
$29.90
Avg Beat Reaction-0.07%
Avg Miss Reaction+22.12%
Beat Rate7 / 8 quarters
Largest Move+22.12% (Q2 FY2010)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PARD ends December
Poniard Pharmaceuticals, Inc. (PARD) most recently reported earnings on March 30, 2011 for Q1 FY2011, posting EPS of $-4.40 — beating the analyst consensus of $-5.00 by +12.0%. PARD has beaten EPS estimates for 3 consecutive quarters. The next PARD earnings date is expected around September 1, 2026.
Each quarter, investors track PARD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PARD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PARD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PARD earnings · 5 questionsPoniard Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PARD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PARD historically reports after market close (AMC).
PARD earnings datewhen is PARD earningsPARD next earnings datewhen does PARD report earningsPARD earnings calendar
▸ Source: FMP · Poniard Pharmaceuticals, Inc. SEC filings · US GAAP · Poniard Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026